Ascend Advanced Therapies
Ascend Advanced Therapies (Ascend) is a specialist adeno-associated virus (AAV) development partner. In-house Gene to GMP capabilities span from early research, including capsid development and vector optimization, to full scale chemistry, manufacturing, and controls (CMC) solutions and comprehensive regulatory guidance and support. Using an acqui-building approach, Ascend hit the ground running in 2023 with operational facilities staffed with industry experts across the United States and Europe.
Working with the Ascend team guarantees a partner with unparalleled insight and collaboration when delivering products from the bench through to commercialization. A flexible platform has been thoughtfully built to support all AAV serotypes across scales with proprietary and partnered technologies including a world-class analytical toolkit. GMP manufacturing capacity was added in 2024 via the acquisition of Beacon Therapeutics, enabling the team to Aim Higher in balancing yield and quality of commercially accessible life-saving therapies.
